by GlobeNewsWire | Jul 11, 2016 | Globe Newswire
TUCSON, Ariz., July 11, 2016 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. (“Accelerate”) announced today the submission of a De Novo request for Evaluation of Automatic Class III Designation to the U.S. Food and Drug Administration (FDA) for its Accelerate...
by GlobeNewsWire | Apr 10, 2016 | Globe Newswire
TUCSON, Ariz., April 10, 2016 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. (“Accelerate”) announced today it will present data related to the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures while attending the European...
by GlobeNewsWire | Dec 15, 2015 | Globe Newswire
TUCSON, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced that it completed a public offering of 6,426,471 shares of common stock today at a previously disclosed price per share of $17.00 which includes 838,235 shares...
by GlobeNewsWire | Dec 9, 2015 | Globe Newswire
TUCSON, Ariz., Dec. 9, 2015 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of the shares are...
by GlobeNewsWire | Dec 8, 2015 | Globe Newswire
TUCSON, Ariz., Dec. 8, 2015 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced that it has commenced an underwritten public offering of $80 million of shares of its common stock. All of the shares are being offered by Accelerate...